Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKZ | Q13574 | 14/20 | 0.43 |
| ▸ | DGKA | P23743 | 5/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900998 | 1.00 | DGKZ (0.43) | DGKZDGKASCDHTR2CTRPA1 | |
| SCHEMBL23527134 | 1.00 | DGKZ (0.43) | DGKZDGKASCDHTR2CTRPA1 | |
| SCHEMBL23564310 | 0.90 | DGKZ (0.43) | DGKZDGKASCDHTR2CTRPA1 | |
| SCHEMBL30900942 | 0.90 | DGKZ (0.43) | DGKZDGKASCDHTR2CTRPA1 | |
| SCHEMBL23526938 | 0.90 | DGKZ (0.43) | DGKZDGKASCDHTR2CTRPA1 | |
| SCHEMBL23564307 | 0.88 | DGKZ (0.48) | DGKZDGKA | |
| SCHEMBL23600164 | 0.87 | SCD (0.47) | DGKZDGKASCDMEN1KMT2A | |
| SCHEMBL23526866 | 0.80 | DGKZ (0.48) | DGKZDGKA | |
| SCHEMBL23564388 | 0.79 | DGKZ (0.47) | DGKZDGKA | |
| SCHEMBL23527125 | 0.79 | DGKZ (0.47) | DGKZDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | DGKZ 2/4885DGKA 1/4885SCD 2447/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | DGKZ 2/4885DGKA 1/4885SCD 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.